カテゴリ： GlobalData, アメリカ, 企業調査

Baxter International Inc (BAX)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Baxter International Inc (BAX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8010869
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月20日
◆ページ数：112
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Baxter International Inc (Baxter) is one of the leading providers of renal and hospital products. It undertakes the development, manufacture and marketing of medical products for the treatment of end-stage renal diseases. Its portfolio include a comprehensive range of home, acute and in-center dialysis solutions, sterile IV solutions, infusion systems, parenteral nutrition, biosurgery products and anesthetics, and pharmacy automation, software and services. The products find application in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers and clinics. The company distributes its products through direct sales force; independent distributors, drug wholesalers acting as sales agents and specialty pharmacies or other alternate site providers. It has wide spread operations in the Americas, the Middle East, Africa, Europe and Asia-Pacific. Baxter is headquartered in Deerfield, Illinois, the US.

Baxter International Inc (BAX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Baxter International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Baxter International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Baxter International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Baxter International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Baxter International Inc, Medical Devices Deals, 2011 to YTD 2017 12
Baxter International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Baxter International Inc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For US$700 Million 16
Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For US$10 Million 18
Baxter International Acquires Ostene Product Line From Ceremed 19
Private Equity 21
Third Point Acquires 7% Stake in Baxter International 21
Partnerships 22
Baxter International Enters into Agreement with Dorizoe Lifesciences 22
Baxter International and Mayo Clinic Enter into Research Agreement 23
Baxter International Enters into Agreement with ScinoPharm Taiwan 24
Kamada Extends Distribution Agreement with Baxter International for Glassia 25
Baxter International Enters Into Co-Development Agreement With Coherus Biosciences 27
Baxter Amends Co-Development Agreement with Coherus Biosciences 28
Kamada Extends Distribution Agreement With Baxter International For Glassia 29
Baxter International Enters Into Agreement With Hemobras For Recombinant FVIII Hemophilia Treatment 31
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 32
Medgenics Extends Co-Development Agreement With Baxter Healthcare 33
Licensing Agreements 34
Baxter International Enters into Licensing Agreement with Merrimack Pharma for MM-398 34
Baxter International Enters Into Licensing Agreement With JW Holdings For Omega 3 Parenteral Nutrition Products 36
Baxter International Enters into Agreement with Laboratoire Aguettant 37
Equity Offering 38
Coherus BioSciences Raises USD10 Million in Private Placement of Shares 38
KaloBios Pharma Completes IPO For US$70 Million 39
Debt Offering 41
Baxter International Prices Public Offering of 1.3% Notes Due 2025 for USD668.2 Million 41
Baxter Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 43
Baxter Completes Public Offering Of Notes Due 2018 For US$750 Million 45
Baxter Completes Public Offering Of Notes Due 2043 For US$500 Million 47
Baxter Completes Public Offering Of Notes Due 2016 For US$500 Million 49
Baxter Completes Public Offering Of Notes Due 2014 For US$500 Million 51
Baxter International Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 53
Asset Transactions 54
Nanotherapeutics Acquires Vero Cell Technology from Baxter 54
Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 55
Vivaldi Biosciences Acquires Influenza Vaccine Assets From Baxter Healthcare 57
West-Ward Pharma Acquires The US Generic Injectables Business From Baxter Healthcare For US$112 Million 59
Hikma Pharma Acquires Multi-Source Injectables Business From Baxter Healthcare For US$112 Million 61
Acquisition 62
Baxter Acquires Claris Injectables for USD625 Million 62
Baxter International Acquires SuppreMol for USD225 Million 64
Baxter Acquires AesRx 65
Baxter International Acquires Chatham Therapeutics from Asklepios BioPharma 66
Guangzhou Pharma Acquires 12.5% Stake In Baxter Healthcare 67
Baxter International Completes Acquisition Of Prism Pharma For US$338 Million 68
Terumo Completes Acquisition Of CaridianBCT From Gambro 70
Baxter International Inc – Key Competitors 72
Baxter International Inc – Key Employees 73
Baxter International Inc – Locations And Subsidiaries 74
Head Office 74
Other Locations & Subsidiaries 74
Joint Venture 80
Recent Developments 81
Strategy And Business Planning 81
May 09, 2016: Baxter Highlights Business Strategies and Innovation at 2016 Investor Conference 81
Financial Announcements 82
Oct 25, 2017: Baxter Reports Third-Quarter 2017 Results and Updates Financial Outlook For Full-Year 2017 82
Jul 26, 2017: Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020 84
Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 86
Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 88
Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 90
Jul 26, 2016: Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016 92
Apr 26, 2016: Baxter Reports First Quarter 2016 Results and Provides Updated Financial Outlook for Full-Year 2016 94
Feb 02, 2016: Baxter Announces Fourth Quarter Results and Provides 2016 Financial Outlook 96
Corporate Communications 98
Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board 98
Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 99
Nov 16, 2016: United Way of Lake County Strengthens Program Providing At-Risk Children with Access to Care 100
Nov 09, 2016: Baxter International Foundation Supports ARVets Initiative to Increase Mental Health Services for Veterans 101
May 05, 2016: Baxter Announces Appointment of Interim President for Its Renal Business 102
Government and Public Interest 103
Nov 17, 2017: Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to address impact of IV fluid shortages following hurricane destruction and resolve manufacturing shortfalls 103
Product News 105
Oct 05, 2017: Baxter Initiates Voluntary Nationwide Recall of One Shipment of Intralipid 20% IV Fat Emulsion Due to Product Being Exposed to Subfreezing Temperatures 105
Sep 27, 2016: Baxter Initiates Voluntary Recall of All Unexpired Lots of 50MM 0.2 Micron Filters 106
Sep 19, 2016: Baxter Launches NUMETA G13E in Europe: Only Ready-to-Use IV Nutrition for Vulnerable Preterm Newborns at Risk for Malnutrition 107
Feb 17, 2016: Baxter Issues Voluntary Nationwide Recall of One Lot of 0.9% Sodium Chloride Solution for Irrigation Due to Presence of Particulate Matter 108
Other Significant Developments 109
Sep 18, 2017: Baxter Parenteral Nutrition Study Describes Lack of Quality Evidence That Fish Lipid Emulsions Significantly Improve Clinical Outcomes 109
Jan 19, 2017: Baxter’s Renal Therapy Services Significantly Reduced Peritonitis Infections among Home Dialysis Patients 110
Sep 22, 2016: The Baxter International Foundation and Direct Relief Launch a Mobile Health Initiative Bringing Life-Saving Medical Treatment and Education to Hundreds of Thousands in Mexico City 111
Appendix 112
Methodology 112
About GlobalData 112
Contact Us 112
Disclaimer 112

List of Tables
Baxter International Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Baxter International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Baxter International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Baxter International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Baxter International Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Baxter International Inc, Medical Devices Deals, 2011 to YTD 2017 12
Baxter International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For US$700 Million 16
Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For US$10 Million 18
Baxter International Acquires Ostene Product Line From Ceremed 19
Third Point Acquires 7% Stake in Baxter International 21
Baxter International Enters into Agreement with Dorizoe Lifesciences 22
Baxter International and Mayo Clinic Enter into Research Agreement 23
Baxter International Enters into Agreement with ScinoPharm Taiwan 24
Kamada Extends Distribution Agreement with Baxter International for Glassia 25
Baxter International Enters Into Co-Development Agreement With Coherus Biosciences 27
Baxter Amends Co-Development Agreement with Coherus Biosciences 28
Kamada Extends Distribution Agreement With Baxter International For Glassia 29
Baxter International Enters Into Agreement With Hemobras For Recombinant FVIII Hemophilia Treatment 31
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 32
Medgenics Extends Co-Development Agreement With Baxter Healthcare 33
Baxter International Enters into Licensing Agreement with Merrimack Pharma for MM-398 34
Baxter International Enters Into Licensing Agreement With JW Holdings For Omega 3 Parenteral Nutrition Products 36
Baxter International Enters into Agreement with Laboratoire Aguettant 37
Coherus BioSciences Raises USD10 Million in Private Placement of Shares 38
KaloBios Pharma Completes IPO For US$70 Million 39
Baxter International Prices Public Offering of 1.3% Notes Due 2025 for USD668.2 Million 41
Baxter Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 43
Baxter Completes Public Offering Of Notes Due 2018 For US$750 Million 45
Baxter Completes Public Offering Of Notes Due 2043 For US$500 Million 47
Baxter Completes Public Offering Of Notes Due 2016 For US$500 Million 49
Baxter Completes Public Offering Of Notes Due 2014 For US$500 Million 51
Baxter International Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 53
Nanotherapeutics Acquires Vero Cell Technology from Baxter 54
Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 55
Vivaldi Biosciences Acquires Influenza Vaccine Assets From Baxter Healthcare 57
West-Ward Pharma Acquires The US Generic Injectables Business From Baxter Healthcare For US$112 Million 59
Hikma Pharma Acquires Multi-Source Injectables Business From Baxter Healthcare For US$112 Million 61
Baxter Acquires Claris Injectables for USD625 Million 62
Baxter International Acquires SuppreMol for USD225 Million 64
Baxter Acquires AesRx 65
Baxter International Acquires Chatham Therapeutics from Asklepios BioPharma 66
Guangzhou Pharma Acquires 12.5% Stake In Baxter Healthcare 67
Baxter International Completes Acquisition Of Prism Pharma For US$338 Million 68
Terumo Completes Acquisition Of CaridianBCT From Gambro 70
Baxter International Inc, Key Competitors 72
Baxter International Inc, Key Employees 73
Baxter International Inc, Other Locations 74
Baxter International Inc, Subsidiaries 74
Baxter International Inc, Joint Venture 80

★海外企業調査レポート[Baxter International Inc (BAX)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • DeepOcean Group Holding BV：企業の戦略的SWOT分析
    DeepOcean Group Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Biglari Holdings Inc.：戦略・SWOT・企業財務分析
    Biglari Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Biglari Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Megapharm Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Megapharm Ltd (Megapharm) is a biotechnology company which offers marketing services. It is engaged in marketing of pharmaceutical products for international companies. Megapharm markets a wide range of products in various therapeutic areas such as dermatology, gastroenterology, central nerv …
  • HSH Nordbank Private Banking：企業の戦略・SWOT・財務情報
    HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • IRX Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary IRX Therapeutics Inc (IRX Therapeutics) is a clinical-stage bioresearch company that develops immunotherapies which reduces the immune suppression. The company provides product that overcomes cancer induced immune suppression and restores anti-tumor response. It offers product IRX-2 which is …
  • Penske Automotive Group, Inc.：企業のM&A・事業提携・投資動向
    Penske Automotive Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Penske Automotive Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Doutor Coffee Co. Ltd.：企業の戦略・SWOT・財務分析
    Doutor Coffee Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Doutor Coffee Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Kraftwerke Oberhasli AG：企業の戦略的SWOT分析
    Kraftwerke Oberhasli AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • EWE AG：企業の戦略的SWOT分析
    EWE AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • The Eat Out Group, SL：企業の戦略・SWOT・財務情報
    The Eat Out Group, SL - Strategy, SWOT and Corporate Finance Report Summary The Eat Out Group, SL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bio-Path Holdings Inc (BPTH)：企業の財務・戦略的SWOT分析
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • Lotte Chemical Corp (011170)：企業の財務・戦略的SWOT分析
    Lotte Chemical Corp (011170) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Culture Landmark Investment Limited：戦略・SWOT・企業財務分析
    Culture Landmark Investment Limited - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Bilfinger Tebodin BV：企業の戦略的SWOT分析
    Bilfinger Tebodin BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Alterity Therapeutics Ltd (PBT)：企業の財務・戦略的SWOT分析
    Summary Alterity Therapeutics Ltd (Alterity Therapeutics) formerly known as Prana Biotechnology Ltd, is a developer of therapeutic drugs. The company is conducting research into Huntington disease, Alzheimer's disease, brain cancer and other major age-related degenerative disorders. It is developing …
  • VidaCaixa, S.A.U. de Seguros y Reaseguros：企業の戦略・SWOT・財務情報
    VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report Summary VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Oncolys BioPharma Inc (4588)：製薬・医療：M&Aディール及び事業提携情報
    Summary Oncolys BioPharma Inc (Oncolys) is a biotechnology company that discovers and develops treatments for cancer and infectious diseases. The company import and export products including drugs and medicines, oncolytic viruses, pharmaceutical pipeline products and tumor diagnostic agents, among o …
  • Regulus Therapeutics Inc (RGLS)：企業の財務・戦略的SWOT分析
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target micr …
  • Toyo Seikan Kaisha, Ltd.：企業の戦略・SWOT・財務情報
    Toyo Seikan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyo Seikan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • LHC Group Inc (LHCG)：企業の財務・戦略的SWOT分析
    Summary LHC Group Inc (LHC Group) is an in-home healthcare service provider. The center offers home health, hospice, personal care services and facility-based services. It covers a range of healthcare needs for patients and families dealing with illness, injury, and chronic conditions. LHC Group pro …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆